🟢 Tenax Therapeutics is trading 10.47% up today after LEVEL trial missed primary and secondary endpoints

Tenax Therapeutics is trading 10.47% up now at $1.90, rebounding after the August 10, 2026 collapse triggered by disappointing Phase 3 LEVEL trial results.

• The study missed its primary and key secondary endpoints.
• The company plans to seek an FDA Type C Meeting regarding TNX-103’s development.
• Broader risk appetite improved on August 13, 2026, after softer-than-expected PPI data supported higher equities.